Metaverse Leader ImmersiveTouch Wins FDA Clearance For New Suite of Medical Diagnosis and Treatment Planning Tools
The newest 510(k) Clearance allows ImmersiveTouch to offer its virtual reality product suite to more radiologists and surgeons.
CHICAGO–(BUSINESS WIRE)–#AI–ImmersiveTouch, a leading medical technology company building the digital surgery metaverse, announced today in conjunction with RSNA 2021 that it received Food and Drug Administration (FDA) 510(k) Clearance for its modular software package that allows users to import, visualize, and automatically segment medical images to create accurate 3-dimensional representations. Giving surgeons the capability to diagnose and treat patients virtually will reduce planning hours and increase efficiency which is crucial for both physicians and patients.
The segmented 3D models can be utilized for medical diagnosis, anatomical measuring, treatment planning, and generating output files for additive manufacturing. ImmersiveTouch is the first automatic patient-specific segmentation technology for generating virtual reality surgical plans which has been utilized in more than 900 procedures this year and is currently deployed in nearly 70 top-tier hospitals.
Dr. Matthew Ranzer, M.D. of plastic surgery at Mount Sinai Hospital says, “One of the things that I like about ImmersiveTouch is that it’s not expensive, but it adds value to our system. The ability to simulate these surgical procedures in fine detail, makes our operations more efficient and safer for our patients and provides a real benefit to our hospital and community.”
The healthcare metaverse is on the rise. According to a research study published by Facts and Factors, the market size for Virtual Reality in Healthcare is expected to grow by a CAGR of 34.89% to $40.98 billion by 2026, up from $2.70 billion in 2020.
“As the healthcare industry really starts to embrace technological advancements, we are able to help reduce surgical planning and operative times, improving surgical efficiency and minimizing workflow disruptions,” says Pat Banerjee, CEO, ImmersiveTouch.
ImmersiveTouch’s COO, Jay Banerjee says, “adding this additional FDA 510(k) Clearance for medical diagnosis and treatment planning to our portfolio just strengthens what ImmersiveTouch can offer surgeons.”
About ImmersiveTouch, Inc.
ImmersiveTouch empowers clinicians with greater precision and consistency of care using technology to simulate each patient’s unique pathology in 3D through its immersive VR metaverse. The company’s proprietary platform integrates solutions for surgical planning, training, and patient engagement. www.immersivetouch.com/
Contacts
Lynne Flakus
lflakus@immersivetouch.com
